New drug cocktail aims to boost chemo for rare childhood cancer
NCT ID NCT01189643
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 26 times
Summary
This study is for people aged 1 to 30 who have just been diagnosed with a rare cancer called desmoplastic small round cell tumor (DSRCT). Researchers are adding three drugs—irinotecan, temozolomide, and bevacizumab—to the usual chemotherapy to see if the combination is safe and tolerable. The goal is to understand the side effects and whether this approach can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.